References
- Gallacher SJ, Boyle IT, Capell HA. Pseudogout associated with the use of cyclical etidronate therapy. Scott Med J 1991;36(2):49.
- Young-Min SA, Herbert L, Dick M, Fordham J. Weekly alendronate-induced acute pseudogout. Rheumatology (Oxford) 2005;44(1):131–2.
- Malnick SD, Ariel-Ronen S, Evron E, Sthoeger ZM. Acute pseudogout as a complication of pamidronate. Ann Pharmacother 1997;31(4):499–500.
- Japan Osteoporosis Society. Guidelines 2004. Osteoporosis Japan 2004;12:191–207.
- Walton RJ, Russell RG, Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med 1975;49(1):45–56.
- Terkeltaub RA. Clinical trials review: crystal deposition diseases. Curr Rheumatol Rep 1999;1(2):97–100.
- Shinozaki T, Pritzker KP. Regulation of alkaline phosphatase: implications for calcium pyrophosphate dihydrate crystal dissolution and other alkaline phosphatase functions. J Rheumatol 1996; 23(4):677–83.
- Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary hyperparathyroidism. Surgery 1989;106(6):1036–41; discussion 41–2.
- Gallagher JC, Riggs BL, Jerpbak CM, Arnaud CD. The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women. J Lab Clin Med 1980;95(3):373–85.